German lawmakers voted through a healthcare reform package designed to cut statutory health insurance costs next year, including higher mandatory rebates on branded medicines. Despite resistance from drugmakers and trade groups, the Bundestag approved the package and the Bundesrat cleared the way for implementation. The measures increase the fixed markdown drugmakers must pay on list prices from 7% to 15.5%, while variable rebate proposals were removed after industry opposition. The reforms are projected to save about 16.3 billion euros in 2027, with potential savings rising substantially by 2030. For biotech and pharma, the package reinforces a pricing environment where innovation can be rewarded unevenly, but rebate mechanics directly affect commercial forecasts and portfolio strategies in one of Europe’s key markets.